Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Operating Leases (2019 - 2024)

Palisade Bio has reported Operating Leases over the past 6 years, most recently at $24000.0 for Q2 2024.

  • Quarterly Operating Leases fell 84.31% to $24000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $24000.0 through Jun 2024, down 84.31% year-over-year, with the annual reading at $90000.0 for FY2023, 57.35% down from the prior year.
  • Operating Leases was $24000.0 for Q2 2024 at Palisade Bio, down from $58000.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $364000.0 in Q2 2022 and troughed at $17000.0 in Q2 2021.
  • The 5-year median for Operating Leases is $136395.0 (2020), against an average of $143637.7.
  • Year-over-year, Operating Leases plummeted 86.8% in 2021 and then surged 2041.18% in 2022.
  • A 5-year view of Operating Leases shows it stood at $112000.0 in 2020, then surged by 41.07% to $158000.0 in 2021, then skyrocketed by 33.54% to $211000.0 in 2022, then crashed by 57.35% to $90000.0 in 2023, then crashed by 73.33% to $24000.0 in 2024.
  • Per Business Quant, the three most recent readings for PALI's Operating Leases are $24000.0 (Q2 2024), $58000.0 (Q1 2024), and $90000.0 (Q4 2023).